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tions weeks after the cure of the initial episode. Although
CQ remains the ﬁrst line of treatment for patients with vivax
malaria in most of the world, CQ monotherapy is now vir-
tually ineffective in Papua Indonesia with signiﬁcant clinical
resistance apparent throughout the Indonesian archipelago.
Sporadic cases have been reported from South America and
Asia. Unfortunately, the mechanism of P. vivax CQ resistance
is largely unknown and as yet no genetic markers have been
identiﬁed.
Since clinical studies are difﬁcult to carry out in this
species due to factors such as individual variations in patient
immune status, reinfections and frequent relapses, and in
vitro susceptibility assays applicability is limited by lack of
culture methods, the global prevalence of CQ resistance to
P. vivax continues to be poorly deﬁned.
Primaquine, an 8-aminoquinoline compound, is the only
commercially available drug with hypnozoitocidal activity
against P. vivax and is widely used for terminal prophy-
laxis; yet, little is known about how the drug works, if it
works, or how it fails. Reports of true PQ failure and subse-
quent P. vivax relapse are unusual. Most suspected cases can
be ascribed to poor patient adherence. The lack of effec-
tive alternatives to PQ against hypnozoites represents an
important drawback in clinical practice andmay be as opera-
tionally crippling to control efforts against P. vivax, as having
no access to insecticides, bed nets, reliable diagnostics, or
chemoprophylaxis.
Plasmodium vivax malaria will linger as a persistent
and severe challenge to public health as long as our
drug armamentarium remains limited and substantial areas
of our knowledge on its biology, epidemiology, genetics,
metabolism, and mechanisms of resistance to antimalarials,
remain obscure.
doi:10.1016/j.ijid.2010.02.2198
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Background: Reassortment, which is the rearrangement
of viral gene segments in a host cell infected with two
different viruses, is an important mechanism for the evo-
lution of inﬂuenza viruses. A mixed infection of more than
one virus could lead to reassortment. To better understand
the occurrence of quasispecies in one host, we investigated
mixed infection in individual isolates for seasonal inﬂuenza
A viruses using amantadine sensitivity as a marker.
Methods: We cultured viruses with amantadine, and per-
formed sequencing, RFLP, cloning, and quantitative PCR to
detect mixed population in clinical samples.Results: Culturing with amantadine shows evidence of a
high number of mixed populations. When sensitive isolates,
whose M genes were in a certain lineage, were cultured in
medium with amantadine, the viruses with M genes from
a different lineage appeared after several passages. In con-
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rast, the other assays can hardly detect mixed populations.
he proportion of minor viruses in the mixed population may
e too small to be identiﬁed by these assays. We showed
considerably higher proportion (at least 6/11) of mixed
opulations in analyzed samples.
Conclusion: The existence of quasispecies in each isolate
s common. However, the proportion of these, which can be
ess than 1%, is too low to be detected by conventional meth-
ds. Such mixed populations, in which reassortment occurs,
ay have a signiﬁcant role in the evolution of viruses.
oi:10.1016/j.ijid.2010.02.2199
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Background: Despite efforts to enhance inﬂuenza vac-
ination among persons at highest risk of complications,
nﬂuenza remains a health burden in the United States.
vidence indicates that vaccination of elementary school
hildren protects them from inﬂuenza, and reduces trans-
ission. However, there are no published intervention trials
emonstrating the impact of strategies designed to enhance
nﬂuenza vaccination rates speciﬁcally among adolescents.
Objective: Assessing the efﬁcacy of twomulti-component
nterventions designed to enhance inﬂuenza vaccination
ates among adolescents attending middle- and high-schools
n three rural counties in Georgia, U.S.A.
Methods: This study employs a non-randomized, three-
rmed controlled design across 2 years. The three arms
onsist of: 1) a multi-component school-based inﬂuenza
accination intervention condition (County 1), 2) a multi-
omponent provider-based inﬂuenza vaccination condition
County 2), and 3) a standard of care condition (County
). The multi-component interventions each consisted of
structural component (school-based or provider-based
rovision of inﬂuenza vaccination) and an educational com-
onent (a brochure and a school skit), designed to enhance
accine education among adolescents and their parents.
Results: During the 2008 to 2009 inﬂuenza season in
ounty 1, there were 70 students vaccinated out of 370 stu-
ents (18.9%). During the same year in County 2, there were
10 out of 736 students vaccinated (14.9%). In the ﬁrst year,
tudents in County 1 were 25% more likely to be vaccinated
han students in County 2 (RR = 1.26, 95% CI: 0.96-1.66). Dur-
ng the current 2009-2010 inﬂuenza season, in County 1 we
ave vaccinated 114 out of 375 students (30.4%), a 62.2%
ncrease from the previous inﬂuenza vaccination season.
